Fulgent Genetics (NASDAQ: FLGT) — Perfil da empresa, notícias e dados financeiros
Fulgent Genetics specializes in genetic testing and next-generation sequencing solutions, enhancing personalized medicine and disease diagnosis.
Fulgent Genetics
Fulgent Genetics (NASDAQ:FLGT) specializes in comprehensive genetic testing and next-generation sequencing solutions, catering to both individuals and healthcare providers. This company leverages advanced technologies and a vast gene database to offer an extensive range of genetic screening and testing services aiming at improving disease diagnosis, treatments, and preventative healthcare measures. Fulgent Genetics is committed to expanding its portfolio of genetic tests, enhancing the accuracy and accessibility of personalized medicine, and continuously invests in research and development to stay at the forefront of genomic diagnostics. Its objectives include making genetic testing more affordable, broadening its test offerings, and extending its global reach to impact patient care worldwide.
Resumo
Operações
Produtos e/ou serviços de Fulgent Genetics
- Comprehensive genetic testing services offering insights into genetic disorders, inherited conditions, and cancers.
- COVID-19 testing kits and services, including RT-PCR tests, for individuals and organizations.
- Next-generation sequencing (NGS) services for detailed genome analysis, supporting research and clinical applications.
- Beacon bioinformatics platform, providing data analysis, storage, and sharing for genetic information.
- Fulgent Pharma, developing targeted therapy cancer drugs leveraging genetic insights.
- Wellness tests covering a range of health indicators, from nutrient levels to heart health, empowering personalized health management.
equipe executiva do Fulgent Genetics
- Ming HsiehChairman & CEO
- Jian XieCOO & President
- Paul KimChief Financial Officer
- Hanlin GaoChief Scientific Officer & Lab Director
- Natalie PrescottGeneral Counsel & Chief Privacy Officer
- Doreen NgVice President of Operations & Compliance
- Jakub SramVice President of Business Development & Sales
- Ellen TsuiVice President of Human Resources
- Brandon PerthuisChief Commercial Officer
- Elias NyankojoChief Information Security Officer
Principais indicadores financeiros
Resultados divulgados pela Fulgent Genetics, em USD.
- Cap. de mercado
- 592,1 mi
- Receita (TTM)
- 323,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.8
- Dividend yield
- —
- Margem de lucro
- -26.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 322,7 mi | -91,1 mi | -60,5 mi | |
| 283,5 mi | -73,9 mi | -42,7 mi | |
| 289,2 mi | -195,5 mi | -167,8 mi | |
| 619 mi | 178,5 mi | 143,4 mi |